Company overview
DiaCarta provides highly sensitive qPCR-based assays and technologies like XNA clamping and SuperbDNA for detecting rare mutations in oncology, including lung, colorectal, bladder, and pan-cancer panels. Their solutions support liquid biopsy, FFPE samples, and work on existing lab instruments for rapid, cost-effective diagnostics. They offer CLIA-certified services and research-use-only testing for precision medicine applications.
Diacarta is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing partner serving United States & Americas. Core focus areas include diacarta, liquid biopsy, xna technology, qpcr assays, cancer mutation detection, clia lab.
Industry categories: Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with Diacarta include Assay, Pcr — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.diacarta.com
- Categories
- Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- diacarta, liquid biopsy, xna technology, qpcr assays, cancer mutation detection, clia lab, precision oncology
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What technologies does DiaCarta offer for mutation detection?
- DiaCarta offers XNA molecular clamp technology for ultrasensitive qPCR assays detecting mutations down to 0.1% LoD, SuperbDNA for signal amplification, and DigiPlex for multiplexing proteins and DNA.
- What cancer assays are available from DiaCarta?
- DiaCarta provides QClamp kits for KRAS, NRAS, EGFR, BRAF, PIK3CA, JAK2, c-KIT mutations, plus multiplex panels like ColoScape for colorectal cancer, and assays for bladder, pan-cancer, cervical, head and neck cancers.
- Does DiaCarta offer CLIA-certified services and global support?
- Yes, DiaCarta operates a CLIA-certified lab with expertise in genomic testing for clinical trials, supporting global operations and high-quality certifications for precision diagnostics.
Related editorial coverage
- Tissue TMB Superior to Blood TMB in Predicting Immunotherapy Response, Cleveland Clinic Study Finds
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
Explore lab tools and QA/QC resources for R&D teams.
